Evidence map›Paper›PMID 28231334›Full record

ArticlePloS one2017

Prevalence of HPV 16 and 18 and attitudes toward HPV vaccination trials in patients with cervical cancer in Mali.

Ibrahima Téguété, Amadou Dolo, Kotou Sangare, Abdoulaye Sissoko, Mali Rochas, Sarah Beseme, Karamoko Tounkara, Shahla Yekta, Anne S De Groot, Ousmane A Koita

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Ibrahima TéguétéHôpital Gabriel Touré, Bamako, Mali.
Amadou DoloHôpital Gabriel Touré, Bamako, Mali.
Kotou SangareLaboratory of Applied Molecular Biology (LBMA), Science and Technologies Faculty (FST), University of Science Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Abdoulaye SissokoLaboratory of Applied Molecular Biology (LBMA), Science and Technologies Faculty (FST), University of Science Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Mali RochasGAIA Vaccine Foundation, Providence, RI, United States of America.
Sarah BesemeGAIA Vaccine Foundation, Providence, RI, United States of America.
Karamoko TounkaraFoundation GAIA, Bamako, Mali.
Shahla YektaGAIA Vaccine Foundation, Providence, RI, United States of America.
Anne S De GrootGAIA Vaccine Foundation, Providence, RI, United States of America.
Ousmane A KoitaLaboratory of Applied Molecular Biology (LBMA), Science and Technologies Faculty (FST), University of Science Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Université des Sciences, des Techniques et des Technologies de Bamako · MLGAIA Vaccine Foundation · USMali-Folkecenter · MLProvidence College · USUniversity of Rhode Island · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCervical cancer is one of the most common and lethal cancers in West Africa. Even though vaccines that protect against the most common Human papillomavirus (HPV) strains, 16 and 18, are currently in use in developed countries, the implementation of these vaccines in developing countries has been painfully slow, considering the pre-eminence of HPV-associated cervical cancer among women in those countries.

aimWe performed serological and PCR-based assessment of blood and tissue specimens obtained from women undergoing cervical cancer-related surgery at a major urban hospital in Bamako. Since several therapeutic HPV vaccines are currently in clinical trials, we also assessed willingness to participate in HPV cancer vaccine trials.

methodsBlood and biopsy samples of 240 women were evaluated for HPV types 16 and 18 by serology and PCR. Knowledge regarding the HPV vaccine and autonomy to decide to vaccinate their own child was assessed with a standardized questionnaire.

resultsHPV 16 and 18 were identified in 137/166 (82.5%) cervical cancer biopsy samples by PCR. Co-infection with both HPV 16 and 18 was significantly more frequent in women over 50 years of age than in younger women (63.0% vs. 37.0%). 44% of study participants said they would be willing to vaccinate their child with HPV vaccine. Only 39% of women participating in this study reported that they would be able to make an autonomous decision to receive HPV vaccination. Permission from a male spouse or head of household was identified as important for participation by 59% of the women.

conclusionThis study provides strong support for the introduction of currently available HPV vaccines in Mali, and also provides key information about conditions for obtaining informed consent for HPV vaccine trials and HPV vaccination in Mali.

Indexed as

Health Knowledge, Attitudes, PracticePapillomavirus VaccinesVaccinationAdultAge FactorsCoinfectionFemaleHuman papillomavirus 16Human papillomavirus 18HumansMaliMiddle AgedPapillomavirus InfectionsUterine Cervical NeoplasmsPapillomavirus Vaccines

Identifiers

PMID28231334
PMCPMC5322926
OpenAlexW2590978672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.